Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 400

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 4
Chunk 400
---
ib were similar in the subgroups with prior target therapy (61.3%) and without prior target therapy (61.1%). This subgroup analysis is consistent with the previously reported results from the FRESCO study’s intent-to-treat population. The results of this analysis showed that fruquintinib had clinically meaningful benefits in 3L CRC patients regardless of prior target therapy without observed cumulative toxicity.
​

Quality-adjusted survival analysis
At ASCO 2018, an analysis was presented that aimed to compare the quality-adjusted survival between the two arms of the FRESCO study using quality-adjusted time without symptoms or toxicity (“Q-TWiST”) methodology. Patients treated with fruquintinib had longer Q-TWiST periods compared to patients treated with placebo. Q-TWiST benefits were observed regardless of prior lines of chemotherapy and prior anti-VEGF or anti-EGFR targeted therapy. The relative improvement of Q-TWiST with fruquintinib represents a clinically important quality-of-life benefit for mCRC patients.
Fruquintinib in Combination with Checkpoint Inhibitors
In November 2018, we entered into a global collaboration with Innovent to evaluate the combination of fruquintinib with Innovent’s Tyvyt, a PD-1 monoclonal antibody approved in China.

         ​             ​                                    ​                                    ​     ​     ​     ​      ​                                          ​                                          ​        ​     
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Treatment                  Trial Name, Patient Focus                                                 Sites       Phase        Status/Plan                                                                           NCT #      
Fruquintinib + Tyvyt       FRUSICA-3: 2L pMMR EMC                                                    China       III          Started Dec 2024                                                                      NCT06584032
Fruquintinib + Tyvyt       FRUSICA-1: 2L pMMR EMC                                                    China       II           Approved and launched in China                                                        NCT03903705
Fruquintinib + Tyvyt   ​   Dose escalation: CRC, BTC, colon cancer, head &amp; neck and others   ​   China   ​   Ib/II    ​   Data presented in ASCO 2024, ESMO Asia 2023, ESMO 2023, ASCO 2023 and CSCO 2021   ​   NCT03903705
                           Dose expansion: EMC, RCC, CRC, HCC, CC, NSCL